The demonstration of activation of IL-1β–associated pathways in humans reinforces the rationale of targeting IL-1β therapeutically and may help to explain the benefits of IL-1β inhibition in the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) of canakinumab in patients after acute coronary syndromes.51 Here, IL1B is linked to acute coronary syndrome.